Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2003 Dec;58(12):1077–1082. doi: 10.1136/thorax.58.12.1077

Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma

V Gerbaudo 1, S Britz-Cunningham 1, D Sugarbaker 1, S Treves 1
PMCID: PMC1746546  PMID: 14645979

Abstract

Background: Malignant pleural mesothelioma is an aggressive neoplasm with a highly variable course. This pilot study evaluated the significance of the pattern, intensity and kinetics of 18F-FDG uptake in mesothelioma in the context of histopathology and surgical staging.

Methods: Sixteen consecutive patients with pleural disease on CT scan underwent 18F-FDG imaging. Imaging was performed with a dual detector gamma camera operating in coincidence mode. Semiquantitative image analysis was performed by obtaining lesion-to-background ratios (18F-FDG uptake index) and calculating the increment of 18F-FDG lesion uptake over time (malignant metabolic potential index (MMPi)).

Results: Twelve patients had histologically proven malignant mesotheliomas (10 epithelial, two sarcomatoid). Thirty two lesions were positive for tumour. Patterns of uptake matched the extent of pleural and parenchymal involvement observed on CT scanning and surgery. Mean (SD) 18F-FDG uptake index for malignant lesions was 3.99 (1.92), range 1.5–9.46. Extrathoracic spread and metastases had higher 18F-FDG uptake indices (5.17 (2)) than primary (3.42 (1.52)) or nodal lesions (2.99 (1)). No correlation was found between histological grade and stage. The intensity of lesion uptake had poor correlation with histological grade but good correlation with surgical stage. 18F-FDG lesion uptake increased over time at a higher rate in patients with more advanced disease. The MMPi was a better predictor of disease aggressiveness than the histological grade.

Conclusions: This pilot study suggests that the pattern, intensity, and kinetics of 18F-FDG uptake in mesothelioma are good indicators of tumour aggressiveness and are superior to the histological grade in this regard.

Full Text

The Full Text of this article is available as a PDF (330.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bengel F. M., Ziegler S. I., Avril N., Weber W., Laubenbacher C., Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med. 1997 Sep;24(9):1091–1098. doi: 10.1007/BF01254239. [DOI] [PubMed] [Google Scholar]
  2. Bury T., Paulus P., Dowlati A., Corhay J. L., Rigo P., Radermecker M. F. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax. 1997 Feb;52(2):187–189. doi: 10.1136/thx.52.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bénard F., Sterman D., Smith R. J., Kaiser L. R., Albelda S. M., Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998 Sep;114(3):713–722. doi: 10.1378/chest.114.3.713. [DOI] [PubMed] [Google Scholar]
  4. Bénard F., Sterman D., Smith R. J., Kaiser L. R., Albelda S. M., Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999 Aug;40(8):1241–1245. [PubMed] [Google Scholar]
  5. Carretta A., Landoni C., Melloni G., Ceresoli G. L., Compierchio A., Fazio F., Zannini P. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Eur J Cardiothorac Surg. 2000 Apr;17(4):377–383. doi: 10.1016/s1010-7940(00)00377-8. [DOI] [PubMed] [Google Scholar]
  6. Corson J. M. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):347–355. [PubMed] [Google Scholar]
  7. Gallagher B. M., Fowler J. S., Gutterson N. I., MacGregor R. R., Wan C. N., Wolf A. P. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978 Oct;19(10):1154–1161. [PubMed] [Google Scholar]
  8. Gerbaudo Victor H., Sugarbaker David J., Britz-Cunningham Scott, Di Carli Marcelo F., Mauceri Charles, Treves S. Ted. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002 Sep;43(9):1144–1149. [PubMed] [Google Scholar]
  9. Imran M. B., Kubota K., Yamada S., Fukuda H., Yamada K., Fujiwara T., Itoh M. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. J Nucl Med. 1998 Jul;39(7):1219–1223. [PubMed] [Google Scholar]
  10. Kotzerke J., Guhlmann A., Moog F., Frickhofen N., Reske S. N. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med. 1999 Jan;26(1):31–38. doi: 10.1007/s002590050356. [DOI] [PubMed] [Google Scholar]
  11. Kubota K., Itoh M., Ozaki K., Ono S., Tashiro M., Yamaguchi K., Akaizawa T., Yamada K., Fukuda H. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001 Jun;28(6):696–703. doi: 10.1007/s002590100537. [DOI] [PubMed] [Google Scholar]
  12. Matthies Alexander, Hickeson Marc, Cuchiara Andrew, Alavi Abass. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002 Jul;43(7):871–875. [PubMed] [Google Scholar]
  13. Nelson C. A., Wang J. Q., Leav I., Crane P. D. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol. 1996 May;23(4):533–541. doi: 10.1016/0969-8051(96)00037-6. [DOI] [PubMed] [Google Scholar]
  14. Pastorino Ugo, Bellomi Massimo, Landoni Claudio, De Fiori Elvio, Arnaldi Patrizia, Picchio Maria, Pelosi Giuseppe, Boyle Peter, Fazio Ferruccio. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003 Aug 23;362(9384):593–597. doi: 10.1016/S0140-6736(03)14188-8. [DOI] [PubMed] [Google Scholar]
  15. Patz E. F., Jr, Rusch V. W., Heelan R. The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. AJR Am J Roentgenol. 1996 Feb;166(2):323–327. doi: 10.2214/ajr.166.2.8553940. [DOI] [PubMed] [Google Scholar]
  16. Pauwels E. K., Ribeiro M. J., Stoot J. H., McCready V. R., Bourguignon M., Mazière B. FDG accumulation and tumor biology. Nucl Med Biol. 1998 May;25(4):317–322. doi: 10.1016/s0969-8051(97)00226-6. [DOI] [PubMed] [Google Scholar]
  17. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997 Feb 1;145(3):211–218. doi: 10.1093/oxfordjournals.aje.a009093. [DOI] [PubMed] [Google Scholar]
  18. Schneider D. B., Clary-Macy C., Challa S., Sasse K. C., Merrick S. H., Hawkins R., Caputo G., Jablons D. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000 Jul;120(1):128–133. doi: 10.1067/mtc.2000.106529. [DOI] [PubMed] [Google Scholar]
  19. Spirtas R., Beebe G. W., Connelly R. R., Wright W. E., Peters J. M., Sherwin R. P., Henderson B. E., Stark A., Kovasznay B. M., Davies J. N. Recent trends in mesothelioma incidence in the United States. Am J Ind Med. 1986;9(5):397–407. doi: 10.1002/ajim.4700090502. [DOI] [PubMed] [Google Scholar]
  20. Sugarbaker D. J., Flores R. M., Jaklitsch M. T., Richards W. G., Strauss G. M., Corson J. M., DeCamp M. M., Jr, Swanson S. J., Bueno R., Lukanich J. M. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999 Jan;117(1):54–65. doi: 10.1016/s0022-5223(99)70469-1. [DOI] [PubMed] [Google Scholar]
  21. Sugarbaker D. J., Garcia J. P., Richards W. G., Harpole D. H., Jr, Healy-Baldini E., DeCamp M. M., Jr, Mentzer S. J., Liptay M. J., Strauss G. M., Swanson S. J. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996 Sep;224(3):288–296. doi: 10.1097/00000658-199609000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sugarbaker D. J., Norberto J. J., Swanson S. J. Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):356–360. [PubMed] [Google Scholar]
  23. Sugarbaker D. J., Strauss G. M., Lynch T. J., Richards W., Mentzer S. J., Lee T. H., Corson J. M., Antman K. H. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993 Jun;11(6):1172–1178. doi: 10.1200/JCO.1993.11.6.1172. [DOI] [PubMed] [Google Scholar]
  24. Waki A., Fujibayashi Y., Yokoyama A. Recent advances in the analyses of the characteristics of tumors on FDG uptake. Nucl Med Biol. 1998 Oct;25(7):589–592. doi: 10.1016/s0969-8051(98)00047-x. [DOI] [PubMed] [Google Scholar]
  25. Waki A., Fujibayashi Y., Yonekura Y., Sadato N., Ishii Y., Yokoyama A. Reassessment of FDG uptake in tumor cells: high FDG uptake as a reflection of oxygen-independent glycolysis dominant energy production. Nucl Med Biol. 1997 Oct;24(7):665–670. doi: 10.1016/s0969-8051(97)00035-8. [DOI] [PubMed] [Google Scholar]
  26. Wiebe L. I. FDG metabolism: Quaecumque sunt vera... J Nucl Med. 2001 Nov;42(11):1679–1681. [PubMed] [Google Scholar]
  27. Younes M., Brown R. W., Stephenson M., Gondo M., Cagle P. T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997 Sep 15;80(6):1046–1051. doi: 10.1002/(sici)1097-0142(19970915)80:6<1046::aid-cncr6>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  28. Zhuang H., Pourdehnad M., Lambright E. S., Yamamoto A. J., Lanuti M., Li P., Mozley P. D., Rossman M. D., Albelda S. M., Alavi A. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001 Sep;42(9):1412–1417. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES